This week's View explores the impact of anticoagulation therapy after bioprosthetic aortic valve replacement on valve hemodynamics and clinical outcomes, the relative clinical benefit of adding alirocumab to statins in acute coronary syndrome patients with prior coronary artery bypass grafting, and whether the achievement of N-terminal pro-B-type natriuretic peptide to ≤1000 pg/ml at 90 days with guideline-directed medical therapy predicts outcomes.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Acute Coronary Syndrome, Angina, Unstable, Anticoagulants, Aortic Valve, Apolipoproteins B, Atrial Fibrillation, Biomarkers, Bioprosthesis, Brain Ischemia, Cardiac Surgical Procedures, Cardiomyopathies, Cholesterol, HDL, Coronary Artery Bypass, Coronary Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Echocardiography, Evidence-Based Practice, Fibrinolytic Agents, Heart Failure, Heart Valve Diseases, Heart Valve Prosthesis, Hemodynamics, Hospitalization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypertension, Lipoproteins, Myocardial Infarction, Myocardial Revascularization, Natriuretic Peptide, Brain, Natriuretic Peptides, Outcome Assessment, Health Care, Peptide Fragments, Primary Prevention, Quality of Life, Renal Insufficiency, Chronic, Risk Factors, Secondary Prevention, Stroke, Stroke Volume, Thrombosis, Transcatheter Aortic Valve Replacement, Treatment Outcome, Vascular Diseases, Venous Thromboembolism, Vitamin K, Arrhythmias, Cardiac, Coronary Angiography, Diagnostic Imaging

< Back to Listings